Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer
Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly nam...
Gespeichert in:
Veröffentlicht in: | Integrative cancer therapies 2013-09, Vol.12 (5), p.414-422 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 422 |
---|---|
container_issue | 5 |
container_start_page | 414 |
container_title | Integrative cancer therapies |
container_volume | 12 |
creator | Xu, Yan Zhao, Ai Guang Li, Zhao Yan Zhao, Gang Cai, Yong Zhu, Xiao Hong Cao, Ni Da Yang, Jin Kun Zheng, Jian Gu, Yin Han, Ying Ying Zhu, Ying Jie Yang, Jin Zu Gao, Feng Wang, Qiang |
description | Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC. |
doi_str_mv | 10.1177/1534735412450512 |
format | Article |
fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1428773210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1534735412450512</sage_id><sourcerecordid>1428773210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</originalsourceid><addsrcrecordid>eNp1UctOwzAQtBCI8rpzQj7CIWDHcZweoaItUhFILYJb5Djr1ii1i51U4h_4aFwKHJA47e7s7Eg7g9ApJZeUCnFFOcsE4xlNM044TXfQAeU8TfI-f9nd9CxLNvseOgzhlZCUkpzvo16aioLyjB-gj2nn12YtG3wDFrRpsdN45mVtWuNshAcLYyEAHoOv4ngPtVERwefyBxo6v-waibXz-M6uzdx52Ro7x9NVA2AvvhaPEQLbBvxs2gW-rtfSKqjxSIbWG4UHm9Efoz0tmwAn3_UIPQ1vZ4NxMnkY3Q2uJ4liot8mkihOcl3VOecVA6CaQAEK0lpwkRUiPpmpivR1VQiZKy2YkKRgEkCAEhzYETrf6q68e-sgtOXSBAVNIy24LpQ0SwshWHQrUsmWqrwLwYMuV94spX8vKSk3GZR_M4gnZ9_qXbWE-vfgx_RISLaEIOdQvrrOR6PD_4KfD36Pqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428773210</pqid></control><display><type>article</type><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><source>Sage Journals GOLD Open Access 2024</source><creator>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</creator><creatorcontrib>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</creatorcontrib><description>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</description><identifier>ISSN: 1534-7354</identifier><identifier>EISSN: 1552-695X</identifier><identifier>DOI: 10.1177/1534735412450512</identifier><identifier>PMID: 22781545</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Disease Progression ; Drugs, Chinese Herbal - therapeutic use ; Female ; Humans ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Spleen - drug effects ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Survival Analysis ; Young Adult</subject><ispartof>Integrative cancer therapies, 2013-09, Vol.12 (5), p.414-422</ispartof><rights>The Author(s) 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</citedby><cites>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1534735412450512$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1534735412450512$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,861,21947,27834,27905,27906,44926,45314</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1534735412450512?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22781545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yan</creatorcontrib><creatorcontrib>Zhao, Ai Guang</creatorcontrib><creatorcontrib>Li, Zhao Yan</creatorcontrib><creatorcontrib>Zhao, Gang</creatorcontrib><creatorcontrib>Cai, Yong</creatorcontrib><creatorcontrib>Zhu, Xiao Hong</creatorcontrib><creatorcontrib>Cao, Ni Da</creatorcontrib><creatorcontrib>Yang, Jin Kun</creatorcontrib><creatorcontrib>Zheng, Jian</creatorcontrib><creatorcontrib>Gu, Yin</creatorcontrib><creatorcontrib>Han, Ying Ying</creatorcontrib><creatorcontrib>Zhu, Ying Jie</creatorcontrib><creatorcontrib>Yang, Jin Zu</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Wang, Qiang</creatorcontrib><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><title>Integrative cancer therapies</title><addtitle>Integr Cancer Ther</addtitle><description>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Disease Progression</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine, Chinese Traditional</subject><subject>Middle Aged</subject><subject>Spleen - drug effects</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><issn>1534-7354</issn><issn>1552-695X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UctOwzAQtBCI8rpzQj7CIWDHcZweoaItUhFILYJb5Djr1ii1i51U4h_4aFwKHJA47e7s7Eg7g9ApJZeUCnFFOcsE4xlNM044TXfQAeU8TfI-f9nd9CxLNvseOgzhlZCUkpzvo16aioLyjB-gj2nn12YtG3wDFrRpsdN45mVtWuNshAcLYyEAHoOv4ngPtVERwefyBxo6v-waibXz-M6uzdx52Ro7x9NVA2AvvhaPEQLbBvxs2gW-rtfSKqjxSIbWG4UHm9Efoz0tmwAn3_UIPQ1vZ4NxMnkY3Q2uJ4liot8mkihOcl3VOecVA6CaQAEK0lpwkRUiPpmpivR1VQiZKy2YkKRgEkCAEhzYETrf6q68e-sgtOXSBAVNIy24LpQ0SwshWHQrUsmWqrwLwYMuV94spX8vKSk3GZR_M4gnZ9_qXbWE-vfgx_RISLaEIOdQvrrOR6PD_4KfD36Pqw</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Xu, Yan</creator><creator>Zhao, Ai Guang</creator><creator>Li, Zhao Yan</creator><creator>Zhao, Gang</creator><creator>Cai, Yong</creator><creator>Zhu, Xiao Hong</creator><creator>Cao, Ni Da</creator><creator>Yang, Jin Kun</creator><creator>Zheng, Jian</creator><creator>Gu, Yin</creator><creator>Han, Ying Ying</creator><creator>Zhu, Ying Jie</creator><creator>Yang, Jin Zu</creator><creator>Gao, Feng</creator><creator>Wang, Qiang</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><author>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Disease Progression</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine, Chinese Traditional</topic><topic>Middle Aged</topic><topic>Spleen - drug effects</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yan</creatorcontrib><creatorcontrib>Zhao, Ai Guang</creatorcontrib><creatorcontrib>Li, Zhao Yan</creatorcontrib><creatorcontrib>Zhao, Gang</creatorcontrib><creatorcontrib>Cai, Yong</creatorcontrib><creatorcontrib>Zhu, Xiao Hong</creatorcontrib><creatorcontrib>Cao, Ni Da</creatorcontrib><creatorcontrib>Yang, Jin Kun</creatorcontrib><creatorcontrib>Zheng, Jian</creatorcontrib><creatorcontrib>Gu, Yin</creatorcontrib><creatorcontrib>Han, Ying Ying</creatorcontrib><creatorcontrib>Zhu, Ying Jie</creatorcontrib><creatorcontrib>Yang, Jin Zu</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Wang, Qiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Integrative cancer therapies</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Xu, Yan</au><au>Zhao, Ai Guang</au><au>Li, Zhao Yan</au><au>Zhao, Gang</au><au>Cai, Yong</au><au>Zhu, Xiao Hong</au><au>Cao, Ni Da</au><au>Yang, Jin Kun</au><au>Zheng, Jian</au><au>Gu, Yin</au><au>Han, Ying Ying</au><au>Zhu, Ying Jie</au><au>Yang, Jin Zu</au><au>Gao, Feng</au><au>Wang, Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</atitle><jtitle>Integrative cancer therapies</jtitle><addtitle>Integr Cancer Ther</addtitle><date>2013-09</date><risdate>2013</risdate><volume>12</volume><issue>5</issue><spage>414</spage><epage>422</epage><pages>414-422</pages><issn>1534-7354</issn><eissn>1552-695X</eissn><abstract>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>22781545</pmid><doi>10.1177/1534735412450512</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 1534-7354 |
ispartof | Integrative cancer therapies, 2013-09, Vol.12 (5), p.414-422 |
issn | 1534-7354 1552-695X |
language | eng |
recordid | cdi_proquest_miscellaneous_1428773210 |
source | Sage Journals GOLD Open Access 2024 |
subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Disease Progression Drugs, Chinese Herbal - therapeutic use Female Humans Male Medicine, Chinese Traditional Middle Aged Spleen - drug effects Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Survival Analysis Young Adult |
title | Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A42%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Benefit%20of%20Traditional%20Chinese%20Herbal%20Medicine%20(a%20Herbal%20Formula%20for%20Invigorating%20Spleen)%20for%20Patients%20With%20Advanced%20Gastric%20Cancer&rft.jtitle=Integrative%20cancer%20therapies&rft.au=Xu,%20Yan&rft.date=2013-09&rft.volume=12&rft.issue=5&rft.spage=414&rft.epage=422&rft.pages=414-422&rft.issn=1534-7354&rft.eissn=1552-695X&rft_id=info:doi/10.1177/1534735412450512&rft_dat=%3Cproquest_AFRWT%3E1428773210%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428773210&rft_id=info:pmid/22781545&rft_sage_id=10.1177_1534735412450512&rfr_iscdi=true |